336 research outputs found
Integrative Pathway Analysis Using Graph-Based Learning with Applications to TCGA Colon and Ovarian Data
published_or_final_versio
Comparison of experiment and theory for superelastic electron-collision studies from laser-aligned magnesium
A combined experimental and theoretical study of superelastic electron collisions from laser-aligned magnesium atoms for a range of collision energies from 35 to 55 eV is presented. 24Mg atoms were excited from the 3 1S0 ground state to the 3 1P1 excited state using continuous-wave linearly polarized laser radiation at ∼285 nm. Electrons of well-defined energy Einc then deexcited the targets, and the superelastically scattered electrons emerging from the collision were detected as a function of scattering angle and laser polarization. Results for alignment of the target by the electron beam are presented for a range of scattering angles, for outgoing energies from Eout=35 to 55 eV. The agreement between the measurements and the results of the convergent close-coupling theory are encouraging, but some discrepancies remain
The initiator methionine tRNA drives secretion of type II collagen from stromal fibroblasts to promote tumor growth and angiogenesis
Summary:
Expression of the initiator methionine tRNA (tRNAi
Met)
is deregulated in cancer. Despite this fact, it is not
currently known how tRNAi
Met expression levels influence
tumor progression. We have found that tRNAi
Met
expression is increased in carcinoma-associated
fibroblasts, implicating deregulated expression of
tRNAi
Met in the tumor stroma as a possible contributor
to tumor progression. To investigate how elevated
stromal tRNAi
Met contributes to tumor progression,
we generated a mouse expressing additional copies
of the tRNAi
Met gene (2+tRNAi
Met mouse). Growth
and vascularization of subcutaneous tumor allografts
was enhanced in 2+tRNAi
Met mice compared with
wild-type littermate controls. Extracellular matrix
(ECM) deposited by fibroblasts from 2+tRNAi
Met
mice supported enhanced endothelial cell and fibroblast
migration. SILAC mass spectrometry indicated
that elevated expression of tRNAi
Met significantly
increased synthesis and secretion of certain types of
collagen, in particular type II collagen. Suppression
of type II collagen opposed the ability of tRNAi
Metoverexpressing
fibroblasts to deposit pro-migratory
ECM. We used the prolyl hydroxylase inhibitor ethyl-
3,4-dihydroxybenzoate (DHB) to determine whether
collagen synthesis contributes to the tRNAi
Met-driven
pro-tumorigenic stroma in vivo. DHB had no effect
on the growth of syngeneic allografts in wild-type
mice but opposed the ability of 2+tRNAi
Met mice to
support increased angiogenesis and tumor growth.
Finally, collagen II expression predicts poor prognosis
in high-grade serous ovarian carcinoma. Taken
together, these data indicate that increased tRNAi
Met
levels contribute to tumor progression by enhancing
the ability of stromal fibroblasts to synthesize and
secrete a type II collagen-rich ECM that supports
endothelial cell migration and angiogenesis
The effect of high dose antibiotic impregnated cement on rate of surgical site infection after hip hemiarthroplasty for fractured neck of femur : a protocol for a double-blind quasi randomised controlled trial
Background:
Mortality following hip hemiarthroplasty is in the range of 10-40% in the first year, with much attributed to post-operative complications. One such complication is surgical site infection (SSI), which at the start of this trial affected 4.68% of patients in the UK having this operation. Compared to SSI rates of elective hip surgery, at less than 1%, this figure is elevated. The aim of this quasi randomised controlled trial (RCT) is to determine if high dose antibiotic impregnated cement can reduce the SSI in patients at 12-months after hemiarthroplasty for intracapsular fractured neck of femur.
Methods:
848 patients with an intracapsular fractured neck of femur requiring a hip hemiarthroplasty are been recruited into this two-centre double-blind quasi RCT. Participants were recruited before surgery and quasi randomised to standard care or intervention group. Participants, statistician and outcome assessors were blind to treatment allocation throughout the study. The intervention consisted of high dose antibiotic impregnated cement consisting of 1 gram Clindamycin and 1 gram of Gentamicin. The primary outcome is Health Protection Agency (HPA) defined deep surgical site infection at 12 months. Secondary outcomes include HPA defined superficial surgical site infection at 30 days, 30 and 90-day mortality, length of hospital stay, critical care stay, and complications.
Discussion:
Large randomised controlled trials assessing the effectiveness of a surgical intervention are uncommon, particularly in the speciality of orthopaedics. The results from this trial will inform evidence-based recommendations for antibiotic impregnated cement in the management of patients with a fractured neck of femur undergoing a hip hemiarthroplasty. If high dose antibiotic impregnated cement is found to be an effective intervention, implementation into clinical practice could improve long-term outcomes for patients undergoing hip hemiarthroplasty
In search of lost introns
Many fundamental questions concerning the emergence and subsequent evolution
of eukaryotic exon-intron organization are still unsettled. Genome-scale
comparative studies, which can shed light on crucial aspects of eukaryotic
evolution, require adequate computational tools.
We describe novel computational methods for studying spliceosomal intron
evolution. Our goal is to give a reliable characterization of the dynamics of
intron evolution. Our algorithmic innovations address the identification of
orthologous introns, and the likelihood-based analysis of intron data. We
discuss a compression method for the evaluation of the likelihood function,
which is noteworthy for phylogenetic likelihood problems in general. We prove
that after preprocessing time, subsequent evaluations take time almost surely in the Yule-Harding random model of -taxon
phylogenies, where is the input sequence length.
We illustrate the practicality of our methods by compiling and analyzing a
data set involving 18 eukaryotes, more than in any other study to date. The
study yields the surprising result that ancestral eukaryotes were fairly
intron-rich. For example, the bilaterian ancestor is estimated to have had more
than 90% as many introns as vertebrates do now
Antenatal corticosteroids and the renin-angiotensin-aldosterone system in adolescents born preterm
Antenatal corticosteroid (ANCS) treatment hastens fetal lung maturity and improves survival of premature infants, but the long-term effects of ANCS are not well-described. Animal models suggest ANCS increases the risk of cardiovascular disease through programmed changes in the renin-angiotensin (Ang)-aldosterone system (RAAS). We hypothesized that ANCS exposure alters the RAAS in adolescents born prematurely
Blood-based markers of efficacy and resistance to cetuximab treatment in metastatic colorectal cancer: results from CALGB 80203 (Alliance)
Circulating protein markers were assessed in patients with colorectal cancer (CRC) treated with cetuximab in CALGB 80203 to identify prognostic and predictive biomarkers. Patients with locally advanced or metastatic CRC received FOLFOX or FOLFIRI chemotherapy (chemo) or chemo in combination with cetuximab. Baseline plasma samples from 152 patients were analyzed for six candidate markers [epidermal growth factor (EGF), heparin-binding EGF (HBEGF), epidermal growth factor receptor (EGFR), HER2, HER3, and CD73]. Analyte levels were associated with survival endpoints using univariate Cox proportional hazards models. Predictive markers were identified using a treatment-by-marker interaction term in the Cox model. Plasma levels of EGF, HBEGF, HER3, and CD73 were prognostic for overall survival (OS) across all patients (KRAS mutant and wild-type). High levels of EGF predicted for lack of OS benefit from cetuximab in KRAS wild-type (WT) patients (chemo HR = 0.98, 95% CI = 0.74-1.29; chemo+cetuximab HR = 1.54, 95% CI = 1.05-2.25; interaction P = 0.045) and benefit from cetuximab in KRAS mutant patients (chemo HR = 1.72, 95% CI = 1.02-2.92; chemo+cetuximab HR = 0.90, 95% CI = 0.67-1.21; interaction P = 0.026). Across all patients, higher HER3 levels were associated with significant OS benefit from cetuximab treatment (chemo HR = 4.82, 95% CI = 1.68-13.84; chemo+cetuximab HR = 0.95, 95% CI = 0.31-2.95; interaction P = 0.046). CD73 was also identified as predictive of OS benefit in KRAS WT patients (chemo HR = 1.28, 95% CI = 0.88-1.84; chemo+cetuximab HR = 0.60, 95% CI = 0.32-1.13; interaction P = 0.049). Although these results are preliminary, and confirmatory studies are necessary before clinical application, the data suggest that HER3 and CD73 may play important roles in the biological response to cetuximab
Blood�based markers of efficacy and resistance to cetuximab treatment in metastatic colorectal cancer: results from CALGB 80203 (Alliance)
Circulating protein markers were assessed in patients with colorectal cancer (CRC) treated with cetuximab in CALGB 80203 to identify prognostic and predictive biomarkers. Patients with locally advanced or metastatic CRC received FOLFOX or FOLFIRI chemotherapy (chemo) or chemo in combination with cetuximab. Baseline plasma samples from 152 patients were analyzed for six candidate markers [epidermal growth factor (EGF), heparin�binding EGF (HBEGF), epidermal growth factor receptor (EGFR), HER2, HER3, and CD73]. Analyte levels were associated with survival endpoints using univariate Cox proportional hazards models. Predictive markers were identified using a treatment�by�marker interaction term in the Cox model. Plasma levels of EGF, HBEGF, HER3, and CD73 were prognostic for overall survival (OS) across all patients (KRAS mutant and wild�type). High levels of EGF predicted for lack of OS benefit from cetuximab in KRAS wild�type (WT) patients (chemo HR = 0.98, 95% CI = 0.74–1.29; chemo+cetuximab HR = 1.54, 95% CI = 1.05–2.25; interaction P = 0.045) and benefit from cetuximab in KRAS mutant patients (chemo HR = 1.72, 95% CI = 1.02–2.92; chemo+cetuximab HR = 0.90, 95% CI = 0.67–1.21; interaction P = 0.026). Across all patients, higher HER3 levels were associated with significant OS benefit from cetuximab treatment (chemo HR = 4.82, 95% CI = 1.68–13.84; chemo+cetuximab HR = 0.95, 95% CI = 0.31–2.95; interaction P = 0.046). CD73 was also identified as predictive of OS benefit in KRAS WT patients (chemo HR = 1.28, 95% CI = 0.88–1.84; chemo+cetuximab HR = 0.60, 95% CI = 0.32–1.13; interaction P = 0.049). Although these results are preliminary, and confirmatory studies are necessary before clinical application, the data suggest that HER3 and CD73 may play important roles in the biological response to cetuximab
Antenatal corticosteroids and cardio-metabolic outcomes in adolescents born with very low birth weight
Exposure to antenatal corticosteroids (ANCS) is associated with adverse cardio-metabolic outcomes in animal models; however long-term outcomes in clinical studies are not well characterized. We hypothesized that exposure to ANCS would be associated with markers of increased cardio-metabolic risk in adolescents born with very low birth weight (VLBW)
CSF1R+ Macrophages Sustain Pancreatic Tumor Growth through T Cell Suppression and Maintenance of Key Gene Programs that Define the Squamous Subtype.
Pancreatic ductal adenocarcinoma (PDAC) is resistant to most therapies including single-agent immunotherapy and has a dense desmoplastic stroma, and most patients present with advanced metastatic disease. We reveal that macrophages are the dominant leukocyte population both in human PDAC stroma and autochthonous models, with an important functional contribution to the squamous subtype of human PDAC. We targeted macrophages in a genetic PDAC model using AZD7507, a potent selective inhibitor of CSF1R. AZD7507 caused shrinkage of established tumors and increased mouse survival in this difficult-to-treat model. Malignant cell proliferation diminished, with increased cell death and an enhanced T cell immune response. Loss of macrophages rewired other features of the TME, with global changes in gene expression akin to switching PDAC subtypes. These changes were markedly different to those elicited when neutrophils were targeted via CXCR2. These results suggest targeting the myeloid cell axis may be particularly efficacious in PDAC, especially with CSF1R inhibitors
- …